VEGFC and lymphedema: Taken together, these findings suggest that inhibition of Th2 cytokines in lymphedema may represent a novel means of improving lymphatic function and decreasing the pathology of the disease without the need for exogenous delivery of VEGF-C or other pro-lymphangiogenic molecules.